Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 348

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 348
---
 of the securities held by KP Biotech.

(13)Consists of (i) 1,735,715 shares of our common stock held directly by Pranabio Investments, LLC (“Pranabio”), (ii) 694,882 shares of our common stock issuable pursuant to currently exercisable warrants that are held by Pranabio, and (iii) 35,780 shares of our common stock held directly by Garden Street House LLC (“Garden Street”). Mr. Samir Patel is the sole manager and member of Pranabio and Garden Street. Mr. Samir Patel disclaims beneficial ownership of the shares held by Pranabio and Garden Street except to the extent of his pecuniary interest therein.

(14)Consists of (i) 473,559 shares of our common stock directly held by the Charles S. Theofilos, MD IRA, an IRA account for Dr. Theofilos’ benefit (the “Theofilos IRA”), (ii) 197,316 shares of our common stock issuable pursuant to currently exercisable warrants that are held by the Theofilos IRA, (iii) 1,506,586 shares of our common stock held directly by Charles S. Theofilos, MD and Kathryn N. Theofilos, as tenants by the entireties (the “Charles and Kathryn”), and (iv) 328,860 shares of our common stock issuable pursuant to currently exercisable warrants that are held by Charles and Kathryn.

112

Item 13.	Certain Relationships and Related Transactions, and Director Independence.

In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers, including those discussed in the section titled “Executive Compensation,” in this Annual Report, the following is a description of each transaction involving our company since January 1, 2024 and each currently proposed transaction in which:

•we have been or are a participant;

•the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of our total assets at year-end for the last two completed fiscal years, as applicable; and

•any of our directors, executive officers or holders of more than 5% of capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.

Warrant Exercise Promissory Notes 

On February 12, 2025, KP Biotech Group, LLC and